Deals In Depth: October 2022
Executive Summary
Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.
You may also be interested in...
Minute Insight: Thermo Fisher Buys Diagnostics Company The Binding Site For $2.6Bn
Birmingham, UK-based The Binding Site and its 1,100 employees will now fall under Thermo Fisher’s expanding umbrella.
Zymeworks Deal Expands Jazz’s Potential Oncology Presence
The deal focuses on the HER2-targeting bispecific antibody zanidatamab, in development for multiple solid tumor indications expressing HER2.
Deals in Depth July 2023
Eight $1bn+ alliances were penned in July. Topping the list was a potential $2.8bn deal under which Alnylam granted Roche exclusive global rights outside the US to develop and commercialize its Phase II hypertension candidate zilebesiran. The companies will co-develop zilebesiran in the US.